Journey Medical (DERM) Asset Writedowns and Impairment (2020 - 2026)
Journey Medical's (DERM) quarterly Asset Writedowns and Impairment came in at $30000.0 in Q1 2026, down 84.62% YoY from $195000.0 in Q1 2025, and up 173.17% on a QoQ basis from -$41000.0 in Q4 2025.
Journey Medical (DERM) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Journey Medical (DERM) has 7 years of Asset Writedowns and Impairment data on file, last reported at $30000.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 84.62% year-over-year to $30000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$376000.0 (down 153.33% YoY) and the FY2025 annual result came in at -$211000.0, down 140.89% from the prior year.
- Asset Writedowns and Impairment grew to $30000.0 in Q1 2026, from -$41000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $3.1 million in Q2 2023 to a low of -$441000.0 in Q2 2025.
- A 5-year average of $218764.7 and a median of $31000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 10038.71% — and 2024, when it plunged 613.95%.
- Tracing DERM's Asset Writedowns and Impairment over 5 years: stood at $274000.0 in 2022, then tumbled by 115.69% to -$43000.0 in 2023, then sank by 613.95% to -$307000.0 in 2024, then jumped by 86.64% to -$41000.0 in 2025, then jumped by 173.17% to $30000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at $30000.0 (Q1 2026), -$41000.0 (Q4 2025), and $76000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Journey Medical | 211.43 Mn | 185.78 Mn | 12.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11,000.00 |
| Jun 30, 2026 | -11,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | -41,000.00 |
| Dec 31, 2025 | -41,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | -441,000.00 |
| Jun 30, 2025 | -441,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Dec 31, 2024 | -307,000.00 |
| Dec 31, 2024 | -307,000.00 |
| Sep 30, 2024 | 671,000.00 |
| Sep 30, 2024 | 671,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |